Last reviewed
7/8/26 → 7/10/26
Conviction●●●●○4 of 5
Research target$724.88Snapshot target
Thesis statusSTRENGTHENEDLast reviewed 7/10/26
Market cap$15.37BSnapshot value
Research history
See all MEDP changes ↗What changed
Conviction
1 → 4
Target
— → $724.88
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Last reviewed
Not reviewed → 7/8/26
Target
— → $724.88
Full-service CRO focused on small- and mid-sized biotech sponsors; the business compounds when biotech funding and trial starts recover, and its Q1/FY2025 growth plus >21% operating margin show the model still has operating leverage.
FY2025 revenue rose 20.0% YoY to $2.53B; Q1 2026 revenue rose 26.5% YoY to $706.6M; recent SEC 8-K earnings-release filings (2026-04-22 and 2026-02-09) confirm ongoing commentary cadence; backlog/book-to-bill still needs direct primary-source validation.
A biotech funding freeze or sustained slowdown in small/mid sponsor demand; rising cancellations; or evidence that backlog/book-to-bill no longer leads recovery would break the leading-indicator thesis.
needs primary source validation; no fresh social sweep in this run
Snapshot · 7/10/26🟡 Mixed · ins-$39.3M · 13F 14+/11- · short↓0.17
Snapshot · 7/10/26